ClinicalTrials.gg
Active, not recruitingNCT05756972Updated Apr 3, 2025

A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC

A Phase 2 interventional study of PM8002 and Carboplatin in NSCLC, sponsored by Biotheus Inc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-03.

Sponsored by Biotheus Inc. (part of BioNTech SE) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
64
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This is a phase II study to evaluate the efficacy and safety of PM8002 in combination with pemetrexed and carboplatin in patients with EGFR-mutant locally advanced or metastatic non-squamous NSCLC who have failed to EGFR-TKI treatment.

Read the detailed description

This study is a phase II, single-arm study, 64 participants were enrolled as of 6 Feb 2024, and recruitment was completed.

02

Conditions studied

  • NSCLC
03

In context

Lead sponsor

Biotheus Inc. is the lead sponsor of 18 studies on the registry; 8 are open to participants now.

First submitted before Biotheus Inc. became part of BioNTech SE.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed form before any trial-related processes.
  2. Age ≥ 18 years male or female.
  3. Have a or cytologically confirmed stage IIIB/IIIC NSCLC that is unresectable and not fit for radical concurrent chemoradiotherapy, or non-squamous NSCLC (IV).
  4. with EGFR mutation confirmed by tumor histology or cytology or hematology prior to EGFR-TKI treatment.
  5. EGFR-TKI resistance, confirmed by v1.1.
  6. have adequate organ function.
  7. The investigator confirms at least one according to RECIST v1.1. A measurable lesion located in the field of previous radiation therapy or after local treatment may be selected as a target lesion if progression is confirmed.
  8. The Eastern Cancer Cooperative Group () performance score of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  1. Squamous cell > 10%. If small cell types are present, the subject is not eligible for inclusion.
  2. Have other driving gene mutations that can obtain effective treatment.
  3. Have previously received systemic anti-tumor treatment other than EGFR-TKI for advanced non-squamous NSCLC.
  4. Have received systemic therapy or any other form of therapy within 14 days prior to the first dose of study drugs.
  5. Have received EGFR-TKI treatment, within 14 days prior to the first dose of study drugs
  6. Anticoagulant or thrombolytic agent within 10 days prior to the first dose of study drugs.
  7. Evidence and history of severe bleeding tendency or coagulation dysfunction.
  8. The toxicity of previous anti-tumor therapy has not been alleviated.
  9. Symptomatic central nervous system (CNS) metastasis and/or cancerous meningitis.
  10. Have suffered from the second primary active malignant tumor in the past 5 years.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    PM8002+Chemotherapy

    Subjects will be administered with PM8002 plus pemetrexed and carboplatin via intravenously (IV) Q3W for 4 cycles, followed by PM8002 and pemetrexed until progression or for a maximum of 2 years.

    Drug: PM8002 · Drug: Carboplatin · Drug: Pemetrexed

Interventions

06

What researchers measure

Primary outcomes

  1. Objective response rate (ORR)

    Objective response rate is the proportion of subjects with complete response (CR) or partial response (PR), based on RECIST v1.1.

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Progression free survival (PFS)

    Progression free survival is defined as the time from the start of treatment until the first documentation of disease progression or death due to any cause, whichever occurs first (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  2. Overall survival (OS)

    OS is the time from the date of randomization or first dosing date to death due to any cause.

    Time frame: Up to approximately 2 years

  3. Disease control rate (DCR)

    DCR is defined as the proportion of subjects with CR, PR, or stable disease(SD) based on RECIST v1.1.

    Time frame: Up to approximately 2 years

  4. Duration of response (DoR)

    DoR is defined as the duration from the first documentation of objective response to the first documented disease progression (based on RECIST v1.1) or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 2 years

  5. Time to response (TTR)

    TTR is defined as the time from the start of the treatment to the first objective tumor response observed for patients who achieve CR or PR (based on RECIST v1.1).

    Time frame: Up to approximately 2 years

  6. Pharmacokinetic (PK) parameters

    The PK parameters include serum concentrations of PM8002 at different timepoints after study drug administration.

    Time frame: Up to 30 days after last treatment

  7. Anti-drug antibody(ADA)

    To evaluate the incidence of ADA to PM8002

    Time frame: Up to 30 days after last treatment

  8. Treatment related adverse events (TRAEs)

    The incidence and severity of TRAEs graded according to NCI-CTCAE v5.0

    Time frame: Up to 30 days after last treatment

  9. Correlation between PD-L1 expression and antitumor effect

    To evaluate correlation between PD-L1 expression and antitumor effect

    Time frame: Up to approximately 2 years

Other outcomes

  1. Population PK analysis

    To assess the Exposure-Response of PM8002 by means of population PK (popPK) analysis

    Time frame: Up to 30 days after last treatment

  2. Correlation between PM8002 exposure, immunogenicity and efficacy

    To evaluate correlation between PM8002 exposure, immunogenicity and efficacy

    Time frame: Up to approximately 2 years

  3. Correlation between PM8002 exposure, immunogenicity and safety

    To evaluate correlation between PM8002 exposure, immunogenicity and safety

    Time frame: Up to 30 days after last treatment

07

Study locations

1 site
  • Medical Ethics Committee of Guangdong Provincial People's Hospital
    Guangzhou, Guangdonng 519041, China
08

References and documents

Individual participant data

Plan to share: Yes — The data will be published or presented for publications (poster, abstract, articles or papers) or any presentations.

Time frame: After the trial completed

Access criteria: NCI is committed to sharing data in accordance with NIH policy.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in Sep 2024, 14 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2023
First posted
Mar 7, 2023
StartActual
Jun 26, 2023
Primary completionActual
Sep 13, 2024
CompletionEst.
Dec 2025
Last update
Apr 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05756972
Lead sponsor
Biotheus Inc.
Responsible party
Sponsor
First posted
Mar 7, 2023
Start date
Jun 26, 2023
Primary completion
Sep 13, 2024
Completion
Dec 2025 (estimated)
Last update
Apr 3, 2025

Study contacts

Wu Yilong, PhD
principal investigator · Guangdong Provincial People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pumitamig

Start the discussion